



Admission of Shares & Total Voting Rights

October 8, 2024

RNS Number : 4004H

Renalytix PLC

08 October 2024

Renalytix plc
("Renalytix" or the "Company")

Admission of Shares & Total Voting Rights

Renalytix (AIM: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that, further to the Company's announcement on 1 October 2024, application has been made to the London Stock Exchange for the admission of the first tranche of new ordinary shares of £0.0025 each ("**Ordinary Shares**") (the "**EIS/VCT Placing Shares**") to trading on AIM. The number of Ordinary Shares in this tranche is 24,007,773 instead of the previously announced 23,174,440, due to a request for additional EIS/VCT Qualifying Shares. Admission of these new Ordinary Shares is expected to take place at or around 8.00 a.m. UK time tomorrow, 9 October 2024.

There is no change to the total fundraise amount or shares to be issued, only the mix between First and Second Admission.

Total Voting Rights

Following the issue of the EIS/VCT Placing Shares, the issued share capital of the Company will consist of 189,933,286 Ordinary Shares. Each Ordinary Share carries one vote and there are no shares held in treasury. Therefore, the total number of voting rights in the Company following admission tomorrow will be 189,933,286 and this figure may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change of their interest in the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Further Admission, Settlement and Dealings

Subject to the Resolutions being passed at the General Meeting on 31 October 2024, application will be made to the London Stock Exchange ("**LSE**") for admission of the 68,766,149 Non-EIS/VCT Placing Shares, the 38,387,634 Subscription Shares and 36,550,543 Conversion Shares to trading on AIM. It is expected that Second Admission will take place at or around 8.00 a.m. UK time on 1 November 2024 and that dealings on AIM will commence at the same time.

Following Second Admission, the Company will have 333,637,612 Ordinary Shares in issue.

Capitalised terms not defined in this announcement have the meanings given to them in the Company's announcement dated 1 October 2024.

The person responsible for making this announcement on behalf of the Company is James McCullough, Chief Executive Officer.

For further information, please contact:

Renalytix Plc
James McCullough, CEO

www.renalytix.com
Via Walbrook PR

Stifel (Nominated Adviser and Joint Broker)
Nicholas Moore / Nick Harland / Ben Good

Tel: 020 7710 7600

Oberon Capital (Joint Broker)
Mike Seabrook / Nick Lovering / Jessica Cave

Tel: 020 3179 5300

Walbrook PR Limited
Paul McManus / Alice Woodings

Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980 541 893 / 07407 804 654

CapComm Partners
Peter DeNardo

Tel: 415-389-6400 or investors@renalytix.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ALSFLFEFILLTIIS